Cet anticorps anti-Filamin A Polyclonal Lapin (ABIN7213236) détecte spécifiquement Filamin A dans WB, IHC, ELISA et IF.
L’anticorps est réactif avec des échantillons de Humain, Souris, Rat et Singe.
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,IHC 1:100-1:300,ELISA 1:10000,IF 1:50-200
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C
Stockage commentaire
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Date de péremption
12 months
Antigène
Filamin A (FLNA)
(Filamin A, alpha (FLNA))
Autre désignation
Filamin 1
Sujet
FLNA, FLN, FLN1, Filamin-A, FLN-A, Actin-binding protein 280, ABP-280, Alpha-filamin, Endothelial actin-binding protein, Filamin-1, Non-muscle filaminFilamin A encoded by FLNA is an actin-binding protein that crosslinks actin filaments and links actin filaments to membrane glycoproteins. Filamin A is involved in remodeling the cytoskeleton to effect changes in cell shape and migration. This protein interacts with integrins, transmembrane receptor complexes, and second messengers. Defects in FLNA are a cause of several syndromes, including periventricular nodular heterotopias (PVNH1, PVNH4), otopalatodigital syndromes (OPD1, OPD2), frontometaphyseal dysplasia (FMD), Melnick-Needles syndrome (MNS), and X-linked congenital idiopathic intestinal pseudoobstruction (CIIPX). Two transcript variants encoding different isoforms have been found for FLNA.